study

RESULTS OF THE MAIRE FOUNDATION STUDY AT COP29 IN BAKU: PEOPLE IN AZERBAIJAN AND KAZAKHSTAN AWARE OF THE URGENCY OF THE ENERGY TRANSITION

55% of Azerbaijani respondents say that the energy transition is a priority, in line with European countries 64% of Azerbaijani…

1 day ago

RESULTS OF THE MAIRE FOUNDATION STUDY AT COP29 IN BAKU: PEOPLE IN AZERBAIJAN AND KAZAKHSTAN AWARE OF THE URGENCY OF THE ENERGY TRANSITION

55% of Azerbaijani respondents say that the energy transition is a priority, in line with European countries 64% of Azerbaijani…

1 day ago

Axtria Unveils New Benchmarking Study on Territory Design and Refinement for Life Sciences Companies

Reveals latest trends in territory alignment, balancing workloads, and enhancing sales effectiveness that can help reshape, inform, and modernize commercial…

1 day ago

Axtria Unveils New Benchmarking Study on Territory Design and Refinement for Life Sciences Companies

Reveals latest trends in territory alignment, balancing workloads, and enhancing sales effectiveness that can help reshape, inform, and modernize commercial…

1 day ago

Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban

November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at the American Heart Association Scientific Sessions show a…

4 days ago

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…

4 days ago

Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban

November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at the American Heart Association Scientific Sessions show a…

4 days ago

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…

4 days ago

Study confirms significance of reducing global greenhouse gas emissions to protect the future of the Olympic Winter Games

12 November 2024 - As world leaders meet at COP29 to agree actions to address the climate crisis, a new study illustrates how…

7 days ago

New Economist Impact Study Finds Only 22% of Enterprises Believe Their IT Infrastructure is Ready for AI

85% of global enterprises are actively using or testing generative AI in at least one function SAN FRANCISCO, Nov. 14,…

7 days ago